{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,24]],"date-time":"2026-07-24T02:43:46Z","timestamp":1784861026367,"version":"3.55.0"},"reference-count":8,"publisher":"Oxford University Press (OUP)","issue":"8","license":[{"start":{"date-parts":[[2022,2,21]],"date-time":"2022-02-21T00:00:00Z","timestamp":1645401600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2022,8,8]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Although indications for immune checkpoint inhibitors (ICIs) have dramatically increased in the past decade, ICIs have been associated with autoinflammatory immune-related adverse events, which can resemble autoimmune diseases (ADs). Little is known about the impact of baseline AD on mortality in cancer patients treated with ICIs. Here, we identified 17\u200a497 patients with preexisting autoimmune diagnoses prior to treatment with antiprogrammed cell death receptor-1 or antiprogrammed cell death ligand-1 therapy and 17\u200a497 matched controls through the TriNetX Diamond network of more than 200 million patients across the United States and Europe. Using a Cox proportional hazards model, we found that patients with history of AD were not at higher risk of mortality than non-AD patients (hazard ratio [HR] = 1.03, 95% confidence interval [CI] = 1 to 1.07; P\u2009=\u2009.05). Additionally, history of Hashimoto disease (HR = 0.75, 95% CI = 0.62 to 0.90; P\u2009=\u2009.002) and vitiligo (HR = 0.52, 95% CI = 0.34 to 0.81; P\u2009=\u2009.003) were statistically significantly associated with decreased mortality. This suggests that underlying AD need not be a contraindication to inclusion in clinical trials and administration of ICI for treatment of cancer.<\/jats:p>","DOI":"10.1093\/jnci\/djac046","type":"journal-article","created":{"date-parts":[[2022,2,17]],"date-time":"2022-02-17T20:11:45Z","timestamp":1645128705000},"page":"1200-1202","source":"Crossref","is-referenced-by-count":22,"title":["Pre-Existing Autoimmune Disease and Mortality in Patients Treated with Anti-PD-1 and Anti-PD-L1 Therapy"],"prefix":"10.1093","volume":"114","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7718-2872","authenticated-orcid":false,"given":"Kimberly","family":"Tang","sequence":"first","affiliation":[{"name":"Department of Dermatology, Massachusetts General Hospital , Boston, MA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bruce C","family":"Tiu","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Massachusetts General Hospital , Boston, MA, USA"},{"name":"Department of Dermatology, Harvard Medical School , Boston, MA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guihong","family":"Wan","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Massachusetts General Hospital , Boston, MA, USA"},{"name":"Department of Biomedical Informatics, Harvard Medical School , Boston, MA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shijia","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Massachusetts General Hospital , Boston, MA, USA"},{"name":"Department of Biomedical Informatics, Harvard Medical School , Boston, MA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nga","family":"Nguyen","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Massachusetts General Hospital , Boston, MA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bonnie","family":"Leung","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Massachusetts General Hospital , Boston, MA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander","family":"Gusev","sequence":"additional","affiliation":[{"name":"Department of Medicine, Dana Farber Cancer Institute , Boston, MA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kerry L","family":"Reynolds","sequence":"additional","affiliation":[{"name":"Department of Medicine, Division of Oncology, Massachusetts General Hospital , Boston, MA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shawn G","family":"Kwatra","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Johns Hopkins University , Baltimore, MD, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7387-3094","authenticated-orcid":false,"given":"Yevgeniy R","family":"Semenov","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Massachusetts General Hospital , Boston, MA, USA"},{"name":"Department of Dermatology, Harvard Medical School , Boston, MA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2022,2,21]]},"reference":[{"issue":"2","key":"2022080904003460600_djac046-B1","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1208\/s12248-021-00574-0","article-title":"Cancer immunotherapy update: FDA-approved checkpoint inhibitors and companion diagnostics","volume":"23","author":"Twomey","year":"2021","journal-title":"AAPS J"},{"issue":"11","key":"2022080904003460600_djac046-B2","doi-asserted-by":"crossref","first-page":"7032","DOI":"10.21037\/jtd-2019-cptn-10","article-title":"Immunotherapy in patients with autoimmune disease","volume":"12","author":"Rakshit","year":"2020","journal-title":"J Thorac Dis"},{"issue":"1","key":"2022080904003460600_djac046-B3","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1186\/s12916-020-01549-2","article-title":"Are immune-related adverse events associated with the efficacy of immune checkpoint inhibitors in patients with cancer? A systematic review and meta-analysis","volume":"18","author":"Zhou","year":"2020","journal-title":"BMC Med"},{"issue":"1","key":"2022080904003460600_djac046-B4","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1007\/s12094-020-02397-5","article-title":"Anti-PD-1\/L1-associated immune-related adverse events as harbinger of favorable clinical outcome: systematic review and meta-analysis","volume":"23","author":"Park","year":"2021","journal-title":"Clin Transl Oncol"},{"issue":"2","key":"2022080904003460600_djac046-B5","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1001\/jamadermatol.2021.5476","article-title":"Association of cutaneous immune-related adverse events with increased survival in patients treated with anti-programmed cell death 1 and anti-programmed cell death ligand 1 therapy","volume":"158","author":"Tang","year":"2022","journal-title":"JAMA Dermatol"},{"issue":"17","key":"2022080904003460600_djac046-B6","doi-asserted-by":"crossref","first-page":"4992","DOI":"10.1158\/1078-0432.CCR-16-3066","article-title":"Immuno-oncology clinical trial design: limitations, challenges, and opportunities","volume":"23","author":"Baik","year":"2017","journal-title":"Clin Cancer Res"},{"key":"2022080904003460600_djac046-B7","doi-asserted-by":"crossref","first-page":"1677","DOI":"10.3389\/fonc.2020.01677","article-title":"Immune-related adverse events and corticosteroid use for cancer-related symptoms are associated with efficacy in patients with non-small cell lung cancer receiving anti-PD-(L)1 blockade agents","volume":"10","author":"Riudavets","year":"2020","journal-title":"Front Oncol"},{"issue":"21","key":"2022080904003460600_djac046-B8","doi-asserted-by":"crossref","first-page":"5993","DOI":"10.1158\/1078-0432.CCR-21-1283","article-title":"Early use of high-dose-glucocorticoid for the management of irAE is associated with poorer survival in patients with advanced melanoma treated with anti-PD-1 monotherapy","volume":"27","author":"Bai","year":"2021","journal-title":"Clin Cancer Res"}],"container-title":["JNCI: Journal of the National Cancer Institute"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jnci\/advance-article-pdf\/doi\/10.1093\/jnci\/djac046\/43402407\/djac046.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jnci\/article-pdf\/114\/8\/1200\/45287952\/djac046.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jnci\/article-pdf\/114\/8\/1200\/45287952\/djac046.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,8,9]],"date-time":"2022-08-09T04:00:52Z","timestamp":1660017652000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jnci\/article\/114\/8\/1200\/6533453"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,2,21]]},"references-count":8,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2022,2,21]]},"published-print":{"date-parts":[[2022,8,8]]}},"URL":"https:\/\/doi.org\/10.1093\/jnci\/djac046","relation":{},"ISSN":["0027-8874","1460-2105"],"issn-type":[{"value":"0027-8874","type":"print"},{"value":"1460-2105","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2022,8,1]]},"published":{"date-parts":[[2022,2,21]]}}}